Abstract
PLANNING DOSE ESCALATION IN PHASE III CLINICAL TRIALS MAY PREVENT UNDERPOWERED TRIALS AND MITIGATE THE INCREASE IN SAMPLE SIZE OR DURATION OF ADAPTIVE TRIALS
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Paper Title
Journal
Date
